Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.

UNLABELLED Hypersensitivity reactions to liposomal drugs, often observed with Doxil and AmBisome, can arise from activation of the complement (C) system by phospholipid bilayers. To understand the mechanism of this adverse immune reaction called C activation-related pseudoallergy (CARPA), we analyzed the relationship among liposome features, C activation in human serum in vitro, and liposome-induced cardiovascular distress in pigs, a model for human CARPA. Among the structural variables (surface charge, presence of saturated, unsaturated, and PEGylated phospholipids, and cisplatin vs. doxorubicin inside liposomes), high negative surface charge and the presence of doxorubicin were significant contributors to reactogenicity both in vitro and in vivo. Morphological analysis suggested that the effect of doxorubicin might be indirect, via distorting the sphericity of liposomes and, if leaked, causing aggregation. The parallelism among C activation, cardiopulmonary reactions in pigs, and high rate of hypersensitivity reactions to Doxil and AmBisome in humans strengthens the utility of the applied tests in predicting the risk of CARPA. FROM THE CLINICAL EDITOR The authors studied complement activation-related pseudoallergy (CARPA) in a porcine model and demonstrate that high negative surface charge and drug effects leading to distortion of liposome sphericity might be the most critical factors leading to CARPA. The applied tests might be used to predict CARPA in humans.

[1]  Nelson Durán,et al.  New aspects of nanopharmaceutical delivery systems. , 2008, Journal of nanoscience and nanotechnology.

[2]  Y. Barenholz,et al.  Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. , 2001, Biochimica et biophysica acta.

[3]  E. Anaissie,et al.  A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia , 2000 .

[4]  V. Torchilin.  Antibody-modified liposomes for cancer chemotherapy. , 2008, Expert Opinion on Drug Delivery.

[5]  Y. Barenholz,et al.  Determination of Critical Micelle Concentration of Lipopolymers and Other Amphiphiles: Comparison of Sound Velocity and Fluorescent Measurements , 2002 .

[6]  J. Szebeni.  Complement Activation-Related Pseudoallergy , 2004 .

[7]  M. Brandl,et al.  Detection of Lipopolysaccharides in Phospholipids and Liposomes Using the Limulus Test , 1995 .

[8]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  Thomas Vorup-Jensen,et al.  Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.

[10]  Y. Talmon.  CRYOGENIC TEMPERATURE TRANSMISSION ELECTRON MICROSCOPY IN THE STUDY OF SURFACTANT SYSTEMS , 1999 .

[11]  D. Alberts,et al.  Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer , 2012, Drugs.

[12]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[13]  M. Bodó,et al.  Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. , 2000, American journal of physiology. Heart and circulatory physiology.

[14]  A. Gabizon,et al.  Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  H. Lenz.  Management and preparedness for infusion and hypersensitivity reactions. , 2007, The oncologist.

[16]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  F M Muggia,et al.  Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.

[18]  A. Aasen,et al.  Studies on the dose dependence of endotoxin-induced in vitro activation of the complement system. , 1989, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

[19]  L E Scriven,et al.  Controlled environment vitrification system: an improved sample preparation technique. , 1988, Journal of electron microscopy technique.

[20]  J. Szebeni,et al.  The interaction of liposomes with the complement system. , 1998, Critical reviews in therapeutic drug carrier systems.

[21]  Y. Barenholz,et al.  Optimization and upscaling of doxorubicin-containing liposomes for clinical use. , 1990, Journal of pharmaceutical sciences.

[22]  H. Takano,et al.  Aggravating Impact of Nanoparticles on Immune-Mediated Pulmonary Inflammation , 2011, TheScientificWorldJournal.

[23]  C. Alving,et al.  Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. , 1995, Artificial cells, blood substitutes, and immobilization biotechnology.

[24]  Y. Barenholz,et al.  Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. , 2005, Chemistry and physics of lipids.

[25]  J Szebeni,et al.  Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. , 2001, International immunopharmacology.

[26]  J Szebeni,et al.  Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. , 1999, Circulation.

[27]  W. D. de Jong,et al.  Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.

[28]  E. Park,et al.  Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse , 2010, Neuroscience.

[29]  Y. Barenholz,et al.  Development of liposomal anthracyclines: from basics to clinical applications. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[30]  M. Bodó,et al.  The interaction of liposomes with the complement system: in vitro and in vivo assays. , 2003, Methods in enzymology.

[31]  H. Lutz,et al.  The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .

[32]  Y. Barenholz,et al.  Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin. , 1997, Biochimica et biophysica acta.

[33]  Y. Barenholz,et al.  Clinical studies of liposome-encapsulated doxorubicin. , 1994, Acta oncologica.

[34]  C. Tilcock,et al.  Studies Upon the Toxicity of Polyethylene Glycol Coated Lipid Vesicles: Acute Hemodynamic Effects, Pyrogenicity and Complement Activation , 1998 .

[35]  M. Bodó,et al.  Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. , 2006, American journal of physiology. Heart and circulatory physiology.

[36]  Yechezkel Barenholz,et al.  Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies. , 2003, Methods in enzymology.

[37]  O. Katare,et al.  Liposomal drug delivery systems--clinical applications. , 2005, Acta pharmaceutica.

[38]  R. Finberg,et al.  Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia , 1999 .

[39]  F M Muggia,et al.  ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES , 2002, Journal of liposome research.

[40]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[41]  B. Binks.  Modern characterization methods of surfactant systems , 1999 .

[42]  D. Pode,et al.  Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer , 2000, Anti-cancer drugs.

[43]  A. Skubitz,et al.  Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™) , 1998, Anti-cancer drugs.

[44]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.